DEF: Creative Medical Technology Holdings Special Meeting Proxy

Creative Medical Technology Holdings, Inc. is holding a special meeting on August 28, 2026, to vote on increasing authorized shares and approving the exercise of investor warrants.

Summary

• Creative Medical Technology Holdings, Inc. is convening a Special Meeting of Stockholders on August 28, 2026, at 9:00 a.m. Pacific Standard Time.
• The primary purposes of the meeting are to vote on an amendment to increase the authorized Common Stock from 25,000,000 to 100,000,000 shares, and to approve the exercise of 5,580,680 Investor Warrants issued in June 2026.
• The record date for voting eligibility is June 30, 2026, with 4,741,236 shares outstanding as of that date.
• The Board of Directors unanimously recommends voting FOR both proposals.
• The meeting requires a quorum of one-third of the voting power of outstanding Common Stock.
• Stockholders can vote in person, via the internet, by telephone, or by mail.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it concerns procedural corporate actions (share increase, warrant exercise approval) rather than performance-based financial results. The potential for dilution is a key consideration.

Positives

• The company is proactively seeking stockholder approval for key corporate actions, demonstrating a commitment to governance.
• The proposed increase in authorized shares provides future flexibility for capital raising, strategic partnerships, and employee incentives.
• Approval of warrant exercise, while dilutive, is presented as a necessary step to avoid repeated meeting costs and comply with agreements.

Negatives

• The proposed increase in authorized shares from 25 million to 100 million represents a significant potential dilution for existing shareholders.
• The exercise of Investor Warrants, if approved, will result in the issuance of 5,580,680 shares, further diluting existing ownership.
• The sale of shares from warrant exercise into the market could negatively impact the stock's market price.

Risks

• The issuance of additional shares could dilute the ownership percentage and voting rights of current stockholders.
• The exercise of warrants and subsequent sale of shares could adversely affect the market price of the company's Common Stock.
• Failure to obtain stockholder approval for warrant exercise could lead to repeated, costly special meetings every 60 days.

Future Outlook

The company is seeking approval to increase its authorized share count to 100 million, providing flexibility for future capital raises, strategic initiatives, and employee incentives. The approval of warrant exercises is a necessary step to comply with agreements and Nasdaq rules, though it will result in dilution.

Management Comments

• The Board of Directors unanimously recommends that stockholders vote FOR the Share Increase Proposal.
• The Board of Directors unanimously recommends a vote FOR the approval of the exercise in full of the Investor Warrants.
• The company is asking stockholders to approve the exercise in full of warrants to purchase an aggregate of 5,580,680 shares of our Common Stock at a price of $1.60 per share.

Industry Context

StockSavvy.ai notes that increasing authorized shares and approving warrant exercises are common strategies for biotechnology and technology companies seeking to maintain financial flexibility for R&D, acquisitions, or operational needs, though they often come with significant dilution concerns for existing shareholders.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution of ownership and voting power due to increased authorized shares and warrant exercise. Also, potential for future capital raises to fund growth.
• Management: Increased flexibility to use equity for incentives and strategic initiatives.
• Institutional Investors: Approval of warrant exercise allows them to convert warrants into shares.

Next Steps

• Stockholders to vote on the proposed amendment to increase authorized shares.
• Stockholders to vote on the approval of the exercise of Investor Warrants.
• If approved, the company expects to promptly file articles of amendment with the Secretary of State of Nevada.
• The company will file a Form 8-K with preliminary voting results within four business days after the Special Meeting.

Key Dates

Recommendation

The filing concerns procedural matters and potential future dilution rather than current financial performance. While the increased authorized shares offer future flexibility, the immediate impact of potential dilution from warrant exercises warrants a cautious 'hold' stance until the strategic use of these shares becomes clearer.

Keywords

Proxy Statement, Special Meeting, Authorized Shares, Stockholder Approval, Warrants, Dilution, Corporate Governance, Nasdaq Listing Rule